

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Fleming Alison B (Last) (First) (Middle) C/O COLLEGIUM PHARMACEUTICAL, INC. 100 TECHNOLOGY CENTER DRIVE (Street) STOUGHTON MA 02072 (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol COLLEGIUM PHARMACEUTICAL, INC [COLL]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) Chief Technical Officer
	3. Date of Earliest Transaction (Month/Day/Year) 01/12/2018	
	4. If Amendment, Date of Original Filed (Month/Day/Year)	

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	01/12/2018 ⁽¹⁾		M		1,747	A	\$0.9	157,911	D	
Common Stock	01/12/2018		s ⁽²⁾		1,747	D	\$21	156,164	D	
Common Stock	01/12/2018		M		5,753	A	\$0.48	161,917	D	
Common Stock	01/12/2018		s ⁽²⁾		5,753	D	\$21	156,164	D	
Common Stock	01/19/2018		M		64	A	\$0.9	156,228	D	
Common Stock	01/19/2018		s ⁽²⁾		64	D	\$23	156,164	D	
Common Stock	01/19/2018		M		1,811	A	\$0.9	157,975	D	
Common Stock	01/19/2018		s ⁽²⁾		1,811	D	\$23	156,164	D	
Common Stock	01/19/2018		M		1,449	A	\$3.31	157,613	D	
Common Stock	01/19/2018		s ⁽²⁾		1,449	D	\$23	156,164	D	
Common Stock	05/10/2018		s ⁽³⁾		1,400	D	\$27	154,764	D	
Common Stock	03/01/2021		s ⁽⁴⁾		6,011	D	\$23.36	148,753	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Option (Right to Purchase)	\$0.9	01/12/2018		M		1,747		(5)	04/23/2019	Common Stock	1,747	\$0	64	D	
Stock Option (Right to Purchase)	\$0.48	01/12/2018		M		5,753		(5)	01/24/2023	Common Stock	5,753	\$0	0	D	
Stock Option (Right to Purchase)	\$0.9	01/19/2018		M		64		(6)	04/23/2019	Common Stock	64	\$0	0	D	
Stock Option (Right to Purchase)	\$0.9	01/19/2018		M		1,811		(6)	02/26/2020	Common Stock	1,811	\$0	0	D	
Stock Option (Right to Purchase)	\$3.31	01/19/2018		M		1,449		(6)	02/08/2021	Common Stock	1,449	\$0	0	D	

Explanation of Responses:

1. Certain transactions reported in this Form 4 are late due to an administrative error.
2. The sales reported in these rows were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2017.
3. The sale reported in this row was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2018.
4. The sale reported in this row was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2020.
5. The option was fully vested and exercisable as of January 12, 2018.
6. The option was fully vested and exercisable as of January 19, 2018.

Remarks:

/s/ Paul Brannelly as Attorney-
In-Fact For Alison B. Fleming

03/03/2021

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.